AI MARKET SCANNING

Atea Pharmaceuticals, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -1.82%
MAX GAP RECORD -14.29%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $AVIR
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 12, 2026 Earnings Release 2026-08-12 (AFTER CLOSE)
+2.96%
Mar 05, 2026 Earnings Release 2026-03-05 (AFTER CLOSE)
-9.06%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
-14.29%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
+5.20%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
-2.03%
Mar 06, 2025 Earnings Release 2025-03-06 (AFTER CLOSE)
-3.67%
Nov 07, 2024 Earnings Release 2024-11-07 (AFTER CLOSE)
+1.45%
Aug 07, 2024 Earnings Release 2024-08-07 (AFTER CLOSE)
+0.31%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.2%
Bullish Gaps (6)
Bearish Gaps (7)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $AVIR

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗